Loading organizations...
Bail Capital is a venture capital firm investing in category-defining companies within stigmatized industries, including cannabis, nicotine, psychedelics, and sex tech. The firm identifies high-potential ventures, providing strategic capital to navigate complex regulatory landscapes. Its approach transforms perceived risks into market opportunities by applying an institutional lens to these unconventional sectors.
James Bailey founded Bail Capital in 2015, driven by the insight that substantial, overlooked potential existed within emerging, stigmatized markets. Leveraging extensive experience from backing influential companies like JUUL and PAX, Bailey provided early institutional capital. His expertise identified future category winners, propelling nascent industries into established market leadership.
Bail Capital serves founders building enterprises in dynamic, regulated environments. The firm’s mission is to provide comprehensive support and capital. Their long-term vision centers on fostering companies that achieve commercial success while legitimizing and redefining their respective stigmatized categories.
Bail Capital has 4 tracked investments across 4 companies. The latest tracked deal is $100.0M Series A in Lykos Therapeutics in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 5, 2024 | Lykos Therapeutics | $100.0M Series A | Suprotik Basu | EIR Therapeutics, KittyHawk Ventures, Satori Neuro, Alexandra M. Cohen, The JOE And Sandy Samberg Foundation, True Ventures, Unlikely Collaborators, Vine Ventures |
| Sep 1, 2021 | Delix Therapeutics | $70.0M Series A | OMX Ventures, Andrew Levin | Vasudev Bailey, ARTIS Ventures, B Capital Group, Negev Capital, Prithvi Ventures, PsyMed Ventures, Satori Capital, Trucks Venture Capital, What IF Ventures, Apeiron Investment Group, Casa Verde Capital, Dolby Family Ventures, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, R^2, Re.Mind Capital, Saya BIO, Vertical Venture Partners, Wpss |
| Dec 23, 2020 | Beckley Psytech | $18.8M Other Equity | — | Noetic Fund |
| Feb 1, 2019 | atai Life Sciences | $13.0M Series B | Michael Auerbach | Endeavor8, Endeavor Venture Funds, Negev Capital, Northpond Ventures, Wilbur Ellis [cavallo], David Ebsworth, Peter Keen, Efrem Kamen, Apeiron Investment Group |